晚期RAS驱动滤泡来源甲状腺癌的特征描述及未来治疗途径综述
该单中心回顾性研究分析了2015年1月至2023年6月期间120例RAS驱动分化型甲状腺癌(DTC)和71例RAS驱动未分化甲状腺癌(ATC)患者,描述其基因型与表型特征。NRAS是最常见变异(DTC 69%,ATC 70%),ATC中位总生存期仅7.5个月,DTC为15.2年。IVC期、颈部手术和免疫治疗暴露与死亡率显著相关。
要点
- NRAS是RAS驱动DTC和ATC中最常见变异,主要位于Q61残基。
- ATC中位总生存期7.5个月,DTC中位总生存期15.2年。
- IVC期(HR=6.78)、颈部手术(HR=0.29)和免疫治疗暴露(HR=0.13)与死亡率显著相关。
核心结论
- 晚期RAS驱动滤泡来源甲状腺癌似乎表现出侵袭性行为,尤其在ATC中尽管接受专家多学科治疗预后仍差。
- RAS靶向治疗的进展为改善治疗选择带来希望。
研究设计与样本
- 回顾性图表审查,时间范围为2015年1月至2023年6月。
- 单中心研究,地点为MD Anderson癌症中心。
- 纳入在激酶抑制剂暴露前鉴定的RAS改变的DTC或ATC患者,共120例RAS驱动DTC和71例RAS驱动ATC。
- DTC队列中位随访时间8.4年,ATC队列中位随访时间36.4个月。
- 无干预措施。
主要发现
- NRAS是最常见变异,占DTC的69%和ATC的70%,主要位于Q61残基。
- 在接受脑成像的患者中,22%发现脑转移(DTC中19%,ATC中25%)。
- DTC中位总生存期为15.2年,49%的患者接受至少1线全身治疗,最常用为仑伐替尼(66%)。
- DTC从诊断到全身治疗的中位时间为3.5年,从治疗开始的中位总生存期为6.0年。
- ATC中位总生存期为7.5个月;IVC期(HR=6.78)、颈部手术(HR=0.29)和免疫治疗暴露(HR=0.13)与死亡率显著相关。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: With novel RAS-targeted therapies emerging, better understanding of RAS-driven differentiated (DTC) and anaplastic (ATC) thyroid cancers is warranted. OBJECTIVE: Characterize the genotypic and phenotypic landscape of RAS-driven DTC and ATC and review current and future therapeutic avenues. DESIGN: Retrospective chart review between January 2015 and June 2023. Median follow-up duration 8.4 years in DTC cohort and 36.4 months in ATC cohort. SETTING: Single-center study at MD Anderson Cancer Center. PATIENTS: Individuals with RAS-altered DTC or ATC identified before kinase inhibitor exposure. INTERVENTIONS: None. MAIN OUTCOME MEASURES: Primary objective was to describe clinical and molecular characteristics. Secondary objectives included identifying prognostic factors and assessing survival outcomes with available therapies. RESULTS: Among 120 RAS-driven DTC and 71 RAS-driven ATC, NRAS was the most common alteration (69% of DTC, 70% of ATC), mainly at residue Q61. Brain metastases were found in 22% of patients undergoing brain imaging (19% in DTC, 25% in ATC). Median overall survival (OS) was 15.2 years in DTC, with 49% of patients receiving at least 1 line of systemic therapy, most commonly lenvatinib (66%). Median time to systemic therapy was 3.5 years from diagnosis, and median OS from therapy initiation was 6.0 years. In ATC, median OS was 7.5 months. Stage IVC [hazard ratio (HR) = 6.78)], neck surgery (HR = 0.29), and exposure to immunotherapy (HR = 0.13) were significantly associated with mortality. CONCLUSION: Advanced RAS-driven follicular-derived thyroid cancers seem to exhibit an aggressive behavior, particularly in ATC, in which prognosis remains poor despite expert multidisciplinary care. Advances in RAS-targeted therapies offer hope for improved therapeutic options.
引用
- Hamidi S, Maniakas A, Akhave NS, et al. Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. J Clin Endocrinol Metab. 2026. PMID: 40568752. doi:10.1210/clinem/dgaf366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。